Effects of pharmacological inhibition of cathepsin K on fracture repair in mice

被引:51
作者
Soung, Do Y. [1 ]
Gentile, Michael A. [2 ]
Duong, Le T. [2 ]
Drissi, Hicham [1 ]
机构
[1] Univ Connecticut, Ctr Hlth, New England Musculoskeletal Inst, Farmington, CT 06030 USA
[2] Merck Res Labs, Bone Biol Grp, West Point, PA 19486 USA
关键词
Cathepsin K; Bone repair; Biomarker; Osteoclast; ENDOCHONDRAL OSSIFICATION; BONE MASS; POSTMENOPAUSAL WOMEN; DEFICIENT MICE; DEGRADATION; OSTEOPOROSIS; ALENDRONATE; RESORPTION; EXPRESSION; ODANACATIB;
D O I
10.1016/j.bone.2013.02.010
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Cathepsin K inhibitors (CatK-I) have been developed and established to restore bone mass in both animal models of bone loss and postmenopausal osteoporotic patients. We investigated the effects of a CatK-I L-006235 on bone repair and compared to alendronate (ALN) for its known effects on fracture healing in pre-clinical models. Femoral fractures were performed on wild type mice that were given vehicle (CON), CatK-I or ALN from day 0 post-fracture until euthanasia. Radiologic and micro-CT analyses demonstrated that CatK-I enhanced mineralization within the calluses at day 21 post-fracture, but to a lesser degree than ALN. Histological analyses showed residual unmineralized and mineralized cartilage in the calluses of CatK-I and ALN treated groups at day 21 post-fracture compared to that in CON. CatK-I enhanced the number of tartrate-resistant acid phosphatase positive (TRAP(+)) osteoclasts in the fracture calluses compared to ALN and CON treated groups. However, relative levels of serum C-terminal telopeptides of type I collagen (CTX) normalized to the number of TRAP(+) osteodasts within the calluses were significantly decreased in both CatK-I and ALN groups compared to CON. Additionally, the percentages of osteoblast surface over mineralized calluses and levels of the bone formation marker serum N-terminal propeptide of type I procollagen (P1NP) were comparable between CatK-I versus CON groups, while these bone formation parameters were decreased by ALN. Taken together, these results indicate that unlike ALN, CatK-I inhibits osteoclastic activity without changing bone formation, and the inhibition of CatK delayed but did not abrogate callus remodeling during bone repair. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:248 / 255
页数:8
相关论文
共 34 条
[1]
Denosumab and bisphosphonates: Different mechanisms of action and effects [J].
Baron, Roland ;
Ferrari, Serge ;
Russell, R. Graham G. .
BONE, 2011, 48 (04) :677-692
[2]
Odanacatib, a Cathepsin-K Inhibitor for Osteoporosis: A Two-Year Study in Postmenopausal Women With Low Bone Density [J].
Bone, Henry G. ;
McClung, Michael R. ;
Roux, Christian ;
Recker, Robert R. ;
Eisman, John A. ;
Verbruggen, Nadia ;
Hustad, Carolyn M. ;
DaSilva, Carolyn ;
Santora, Arthur C. ;
Ince, B. Avery .
JOURNAL OF BONE AND MINERAL RESEARCH, 2010, 25 (05) :937-947
[3]
Novel pycnodysostosis mouse model uncovers cathepsin K function as a potential regulator of osteoclast apoptosis and senescence [J].
Chen, Wei ;
Yang, Shuying ;
Abe, Yoke ;
Li, Ming ;
Wang, Yucheng ;
Shao, Jianzhong ;
Li, En ;
Li, Yi-Ping .
HUMAN MOLECULAR GENETICS, 2007, 16 (04) :410-423
[4]
Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey [J].
Cusick, Tara ;
Chen, Charles M. ;
Pennypacker, Brenda L. ;
Pickarski, Maureen ;
Kimmel, Donald B. ;
Scott, Boyd B. ;
Duong, Le T. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :524-537
[5]
Cleavage of type II collagen by cathepsin K in human osteoarthritic cartilage [J].
Dejica, Valeria M. ;
Mort, John S. ;
Laverty, Sheila ;
Percival, M. David ;
Antoniou, John ;
Zukor, David J. ;
Poole, A. Robin .
AMERICAN JOURNAL OF PATHOLOGY, 2008, 173 (01) :161-169
[6]
Safety and Efficacy of the Cathepsin K Inhibitor ONO-5334 in Postmenopausal Osteoporosis: The OCEAN Study [J].
Eastell, Richard ;
Nagase, Shinichi ;
Ohyama, Michiyo ;
Small, Maria ;
Sawyer, James ;
Boonen, Steven ;
Spector, Tim ;
Kuwayama, Tomohiro ;
Deacon, Steve .
JOURNAL OF BONE AND MINERAL RESEARCH, 2011, 26 (06) :1303-1312
[7]
Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity [J].
Falgueyret, JP ;
Desmarais, S ;
Oballa, R ;
Black, WC ;
Cromlish, W ;
Khougaz, K ;
Lamontagne, S ;
Massé, F ;
Riendeau, D ;
Toulmond, S ;
Percival, MD .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) :7535-7543
[8]
Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts [J].
Fuller, Karen ;
Lawrence, Kevin M. ;
Ross, Jade L. ;
Grabowska, Urszula B. ;
Shiroo, Masahiro ;
Samuelsson, Bertil ;
Chambers, Timothy J. .
BONE, 2008, 42 (01) :200-211
[9]
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial [J].
Garnero, P. ;
Aronstein, W. S. ;
Cohen, S. B. ;
Conaghan, P. G. ;
Cline, G. A. ;
Christiansen, C. ;
Beary, J. F. ;
Meyer, J. M. ;
Bingham, C. O., III .
OSTEOARTHRITIS AND CARTILAGE, 2008, 16 (06) :660-666
[10]
Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI [10.1359/jbmr.081113, 10.1359/JBMR.081113]